Published in final edited form as:

Pancreatology. 2020 June ; 20(4): 781–784. doi:10.1016/j.pan.2020.04.001.

Pediatric chronic pancreatitis without prior acute or acute recurrent pancreatitis: A report from the INSPPIRE consortium

Maisam Abu-El-Haija*

Cincinnati Children's Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

Mark Lowe

Washington University School of Medicine, St. Louis, MO, USA

Bradley Barth

University of Texas Southwestern Medical School, Dallas, TX, USA

Melena D. Bellin

University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA

Douglas S. Fishman

Section of Pediatric Gastroenterology, Hepatology and Nutrition Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA

Steve Freedman

Harvard Medical School, Boston, MA, USA

Cheryl Garipey

Nationwide Children's Hospital, Columbus, OH, USA

Matthew J. Giefer

University of Washington, Seattle Children's Hospital, Seattle, WA, USA

Tanja Gonska

Hospital for Sick Children, Toronto, ON, Canada

Melvin B. Heyman

University of California San Francisco, San Francisco, CA, USA

Ryan Himes

Section of Pediatric Gastroenterology, Hepatology and Nutrition Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA

Sohail Husain

*Corresponding author. maisam.haija@cchmc.org (M. Abu-El-Haija).

Declaration of competing interest

Dr. Mark Lowe is on the Board of Directors of the National Pancreas Association; receives royalties from Millipore Inc and UpToDate. Dr. Tanja Gonska received a research grant from Vertex Pharmaceuticals. Dr. John Pohl is on the speaker's bureau for Medical Education Resources, Inc.; Dr. Melena Bellin is a consultant for AbbVie Inc and ARIEL Precision Medicine. Dr. Chee Y. Ooi is a consultant for Vertex Pharmaceuticals. Dr. Sohail Husain owns equity in PrevCon. Dr. Michael Wilschanski received a research grant from Vertex Pharmaceuticals, Dr. Aliye Uc is a member of American Board of Pediatrics, Subboard of Pediatric Gastroenterology. The other authors declare no conflicts of interest.

Children's Hospital; of Pittsburgh, Pittsburgh, PA, USA

Tom K. Lin

Cincinnati Children's Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

Quin Liu

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Maria R. Mascarenhas, Asim Maqbool

Children's Hospital of Philadelphia, Philadelphia, PA, USA

Brian McFerron

Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA

Veronique Morinville

Montreal Children's Hospital, McGill University, Montreal, QC, Canada

Jaimie Nathan

Cincinnati Children's Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

Chee Y. Ooi

School of Women's and Children's Health, Medicine, University of New South Wales and Sydney Children's Hospital Randwick Sydney, Australia

Emily Perito

University of California San Francisco, San Francisco, CA, USA

John F. Pohl

University of Utah, Salt Lake City, UT, USA

Sarah Jane Schwarzenberg

University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA

Uzma Shah

Massachusetts General Hospital for Children, Harvard Medical School, Boston, MA, USA

David Troendle

University of Texas Southwestern Medical School, Dallas, TX, USA

Steven Werlin

Medical College of Wisconsin, Milwaukee, WI, USA

Michael Wilschanski

Hadassah Hebrew University Hospital, Jerusalem, Israel

Bridget Zimmerman

University of Iowa, Department of Biostatistics, Iowa City, IA, USA

Aliye Uc

University of Iowa, Stead Family Children's Hospital, Iowa City, IA, USA

Keywords

Pediatrics; Pancreatitis; Silent chronic pancreatitis

Dear Editor,

Chronic pancreatitis (CP) is an inflammatory disease resulting in irreversible changes in the pancreas including acinar cell loss, fibrosis, ductal changes and calcifications [1]. Patients with CP suffer from abdominal pain and complications of exocrine pancreatic insufficiency (EPI) and diabetes mellitus [2]. Due to significant implications on child health and well-being, it is essential that childhood CP is recognized early, and sequelae are treated promptly [3].

Our INSPPIRE (**I**nternational **S**tudy group of **P**ediatric **P**ancreatitis: **I**n search for a **cuRE**) study includes children with CP but did not report previous episodes of acute pancreatitis (AP) prior their enrollment. Here, we report the risk factors and clinical phenotypes of children enrolled in INSPPIRE who present “silent CP” [1,4].

Our study design included data collection utilizing patient/parent and physician questionnaires from children who fulfilled the criteria for CP at nineteen INSPPIRE centers and were 19 years of age at the time of enrollment [4,5]. INSPPIRE criteria were used for the diagnosis of AP, ARP and CP as previously reported [1,4]. Patients were grouped in the “traditional CP” cohort “if they reported any history of AP prior to their CP diagnosis, and in “silent CP” cohort, if they did not.

Summary statistics were presented as mean with standard deviation (SD), median with interquartile range (IQR), or frequency count with percentage. Subject characteristics, risks and clinical variables were compared between children with CP and no prior AP or ARP (silent CP, n = 20) and children with CP and AP or ARP episodes prior (traditional CP, n = 185). A p-value <0.05 was considered statistically significant.

Among 205 children with CP, 185 had traditional CP (90%), 20 silent CP (10%). These two groups were not different in age, sex, race, ethnicity or age at diagnosis of CP (Table 1).

Subjects in both groups had genetic risk factors (*PRSS1*, *SPINK 1*, *CFTR*, and *CTRC*), but the differences between the groups were not statistically significant (Table 2). Likewise, the family history of AP or CP, and obstructive and environmental risk factors were also not different. Children with silent CP were more likely to have autoimmune pancreatitis (AIP) compared to traditional CP (20% vs 3%, p = 0.008) (Table 2). Other autoimmune diseases and inflammatory bowel disease (IBD) were not different between the groups.

Table 3 summarizes all imaging findings for ERCP, Computed tomography (CT), Magnetic resonance imaging (MRI/MRCP) and Endoscopic Ultrasound (EUS) during the course of their disease. Results were consistent with imaging findings typical of CP including duct irregularities, pancreatic atrophy, duct dilatation, and calcifications. Findings consistent with acute inflammatory changes in the pancreas were found in both silent and traditional CP if an imaging study was done at initial presentation or at a subsequent evaluation. Ductal

stones were significantly more common in silent CP compared to traditional CP (10/18 [56%] vs 49/161 [30%]; $p = 0.032$); no other differences were observed.

Medical therapy including pancreatic enzymes, pain medications, antioxidants, steroids, and diabetes medications was utilized in 13 of 20 (65%) of the silent CP patients and 126 of 185 (71%) traditional CP patients (Table 4). Corticosteroids were more commonly used in the silent CP group (3/18 [17%]) compared to the traditional CP (4/166 [2%], $p = 0.022$) probably reflecting the increased proportion of AIP in the silent CP group. Overall, no other significant differences were observed in the frequency of endoscopic or surgical therapies between the groups.

Our study demonstrates that CP may occur without prior AP or ARP in children. In the INSPPIRE cohort, one in ten children with CP reported no previous AP episodes. Children with this “silent” presentation are more likely to have AIP, advanced morphological changes, including pancreatic intraductal stones and tendency for chronic pain compared to the traditional presentation. Pediatricians need to be aware of this insidious presentation of CP and consider imaging patients with persistent pain or an episode suggestive of AP. Early recognition of “silent CP” is essential for the timely treatment of underlying causes and associated sequelae.

Funding

Dr. Aliye Uc is supported by the National Institute of Health grants (U01 DK108334, R01 DK118752, R24 DK096518); INSPPIRE registry was developed by CTSA (2UL1 TR000442) and REDCap.

References

- [1]. Morinville VD, Husain SZ, Bai H, Barth B, Alhosh R, Durie PR, et al. Definitions of pediatric pancreatitis and survey of present clinical practices. *J Pediatr Gastroenterol Nutr* 2012;55(3):261–5. [PubMed: 22357117]
- [2]. Schwarzenberg SJ, Bellin M, Husain SZ, Ahuja M, Barth B, Davis H, et al. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. *J Pediatr* 2015;166(4):890–896 e1. [PubMed: 25556020]
- [3]. Kumar S, Ooi CY, Werlin S, Abu-El-Haija M, Barth B, Bellin MD, et al. Risk factors associated with pediatric acute recurrent and chronic pancreatitis: lessons from INSPPIRE. *JAMA Pediatr* 2016;170(6):562–9. [PubMed: 27064572]
- [4]. Morinville VD, Lowe ME, Ahuja M, Barth B, Bellin MD, Davis H, et al. Design and implementation of INSPPIRE. *J Pediatr Gastroenterol Nutr* 2014;59(3):360–4. [PubMed: 24824361]
- [5]. Schwarzenberg SJ, Bellin M, Husain SZ, Ahuja M, Barth B, Davis H, et al. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. *J Pediatr* 2015;166(4):890–896 e1. [PubMed: 25556020]

Table 1

Demographics and clinical characteristics of patients' groups.

Variables	Silent CP (n = 20)	Traditional CP (n = 185)	p-value
Sex (Female)	13 (65%)	105/184 (57%)	0.495
Ethnicity (Hispanic)	3/18 (17%)	31/168 (18%)	1.0
Race	(n = 17)	(n = 162)	0.316
White	15(88%)	131 (81%)	
Multi-racial	0 (0%)	11 (7%)	
African American	0 (0%)	7(4%)	
Asian	2 (12%)	7 (4%)	
Other	0 (0%)	6 (4%)	
Age at first diagnosis		(n = 175)	0.162
Mean (SD)	10.0 (3.2)	8.6 (4.6)	
Range	5.3–16.3	1.0–17.4	

Table 2

Risk factors of CP.

Variables	Silent CP (n = 20)	Traditional CP (n = 185)	p-value
<u>Family history</u>			
Acute pancreatitis	4/16 (25%)	45/145 (31%)	0.778
Chronic pancreatitis	5/18 (28%)	49/151 (32%)	1.0
<u>Genetic Risk Factors:</u>			
PRSS1	9/15 (60%)	66/153 (43%)	0.210
SPINK1	2/14 (14%)	34/136 (25%)	0.520
CFTR	3/14 (21%)	48/147 (33%)	0.551
CTRC	0/7 (0%)	6/95 (6%)	1.0
<u>Obstructive factors</u>			
Pancreas divisum	2/19 (11%)	23/181 (13%)	1.0
<u>Risk factors</u>			
Alcoholic	1 (5%)	4/184 (2%)	0.406
Active smoker	1 (5%)	2/184 (1%)	0.267
Passive smoking exposure	3 (15%)	12/179 (7%)	0.180
Hyperlipidemia	0/18 (0%)	5/159 (3%)	1.0
Medications	1/18 (6%)	10/173 (6%)	1.0
Autoimmune pancreatitis	4 (20%)	4/144 (3%)	0.008
Other autoimmune diseases	1/19 (5%)	12/177 (7%)	1.0
Ulcerative colitis	0/19 (0%)	2/177 (1%)	1.0
Indeterminate colitis/IBD-U	0/19 (0%)	1/176 (1%)	1.0

Cationic trypsinogen (*PRSS1*), Serine Protease Inhibitor Kazal-Type1 (*SPINK1*), Cystic fibrosis transmembrane regulator (*CFTR*) and Chymotrypsin receptor C (*CTRC*).

Table 3

Imaging findings.

Variables	p-value	
	Silent CP (n = 20)	Traditional CP (n = 185)
<u>Imaging studies performed ERCP</u>		
Number ERCP (range)	14 (70%)	129 (70%)
1	(1-7)	(1-9)
2	9	67
3	2	31
4	1	13
CT scan	2	18
MRI (not performed with MRCP)	11 (55%)	102 (55%)
MRCP	3 (15%)	59 (32%)
EUS	14 (70%)	155 (84%)
Findings (CT/MRI)	4 (20%)	32 (17%)
Focal Acute Pancreatitis	3/15 (20%)	24/153 (16%)
Inflammatory changes in Pancreas	6/16 (38%)	57/153 (37%)
Pancreatic Gland Enlargement	2/16 (12%)	25/154 (16%)
Pancreatic Atrophy Present	10/16 (62%)	67/155 (43%)
Calcifications in Pancreas present	4/16 (25%)	24/154 (16%)
Duct Irregularities	11/15 (73%)	89/153 (58%)
Pancreatic duct dilatation present	11/16 (69%)	93/153 (61%)
Lesions present in the pancreas	2/16 (12%)	5/158 (3%)
Gallstones/Sludge	1/15 (7%)	11/156 (7%)
Intrahepatic biliary dilatation	3/16 (19%)	13/154 (8%)
Changes suggestive of cirrhosis and/or portal hypertension	1/15 (7%)	9/154 (6%)
<u>Findings (CT/MRI/MRCP/ERCP)</u>		
Pancreatic duct obstruction (stricture)	5/19 (26%)	67/175 (38%)
CBD stricture (Intrapancreatic portion)	3 (15%)	9/177 (5%)
Dilated CBD	3/19 (16%)	40/178 (22%)
CBD Stone	2 (10%)	10/178 (6%)

Variables	Silent CP	Traditional CP	p-value
	(n = 20)	(n = 185)	
<u>Findings (CT/MRI/EUS)</u>			
Peripancreatic inflammation/fat stranding	3/16 (19%)	58/154 (38%)	0.133
<u>Findings (CT/MRI/MRCP/ERCP/EUS)</u>			
Cysts/Pseudocysts	4 (20%)	41/178 (23%)	1.0
<u>Findings (MRCP/ERCP)</u>			
Main Pancreatic Duct - Abnormal	15/18 (83%)	135/168 (80%)	1.0
Abnormal Side Branches	8/18 (44%)	77/157 (49%)	0.712
Intraductal filling defects of Calculi	10/18 (56%)	49/161 (30%)	0.032
Pancreas Divisum	3/18 (17%)	24/163 (15%)	0.736

Magnetic resonance cholangiopancreatography (MRCP), Endoscopic retrograde cholangiopancreatography (ERCP), Computed tomography (CT), Endoscopic Ultrasound (EUS).

Table 4

Treatment modalities.

Variables	Silent CP	Traditional CP	p-value
	(n = 20)	(n = 185)	
Medical therapies (from provider response)	13 (65%)	126/178 (71%)	0.592
<u>Medications (from patient response)</u>			
Pain medications	5/17 (29%)	81/166 (49%)	0.127
Pancreatic enzymes	7/18 (39%)	95/166 (57%)	0.137
Vitamins/anti-oxidants	7/18 (39%)	81/166 (49%)	0.424
Steroids	3/18 (17%)	4/166 (2%)	0.022
Diabetic medications	0/18 (0%)	18/167 (11%)	0.224
<u>Medication helpful in controlling/treating pancreatitis (from patient response of those using medication)</u>			
Pain medications helpful	3/5 (60%)	47/58 (81%)	0.273
Pancreatic enzymes helpful	2/2 (100%)	43/54 (80%)	–
Vitamins/anti-oxidants helpful	1/5 (20%)	12/40 (30%)	1.0
Steroids helpful	–	3/3 (100%)	–
Diabetic medications helpful	–	6/12 (50%)	–
<u>Procedures</u>			
Any ERCP	14 (70%)	125/179 (70%)	0.988
Biliary sphincterotomy	4 (20%)	45/172 (26%)	0.550
Pancreatic sphincterotomy	9 (45%)	86/170 (51%)	0.636
Pancreatic duct stent	9 (45%)	75/174 (43%)	0.871
Biliary stent	1 (5%)	14/174 (8%)	1.0
Pancreatic duct stone removal	8 (40%)	40/173 (23%)	0.107
<u>Surgeries</u>			
Surgical therapies	4 (20%)	74/180 (41%)	0.066
Cholecystectomy	3 (15%)	33/180 (18%)	1.0
Celiac nerve block	0 (0%)	6/180 (3%)	1.0
Cyst/pseudo-cyst operation	1 (5%)	9/180 (5%)	1.0
Lateral pancreaticojejunostomy	0 (0%)	17/180 (9%)	0.228
Partial pancreatectomy	0 (0%)	4/180 (2%)	1.0

Variables	Traditional CP (n = 185)		p-value
	Silent CP (n = 20)		
Total pancreatectomy/islet auto transplant	3 (15%)	39/179 (22%)	0.577